欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
目的探讨建立多个肿瘤标志物联合检测的luminex液相芯片检测方法。方法应用配对好的AFP、血管内皮生长因子vascular endothelial growth facto，VEGF）、细胞外基质金属蛋白酶诱导因子（extracellular matrixmetalloproteinase inducer，EMMPRIN／CD147）3对单克隆抗体建立3个肿瘤标志物联合检测的luminex液相芯片检测体系并评估其敏感性，交叉反应并将其应用于血浆样本的检测。结果3对抗体在luminex液相芯片系统中无交叉反应，敏感性分别为AFP64pg/ml、CD14740pg／ml、VEGF4pg／ml。应用该体系检测了40例HCC患者，分别为AFP[6．5（2．8，240．0）]ng／ml，CD147（4．11±0．90）ng／ml，VEGF[40（20，50）]pg／ml；40例健康对照组，分别为AFP[0．3（0．1，1．0）]ng／ml，CD147（2．98±0．80）ng／ml，VEGF[10（0，10）]pg／ml。3个肿瘤标志物在肝癌患者外周血中的浓度显著高于正常对照组（P〈0．05）。结论成功建立高敏感性的3个肿瘤标志物联合检测的液相芯片检测体系。
英文摘要：
Objective To develop the luminex liquichip assay for combined tumor markers detection. Methods Paired anti-human AFP, VEGF, CD147 Mabs were applied to develop multi-tumor marker liquichip detection system. Sensitivity, specificity and application it for plasma detection were evaluated. Results There were no cross reaction among three pairs of Mabs and the sensitivity of AFP was 64 pg/ml, CD147 was 40 pg/ml, VEGF was 4 pg/ml. Application it to detect plasm, AFP was 6.5（2.8,240.0）ng/ml, CD147 was （4.1 1±0.90）ng/ml, VEGF was 40（20,50）pg/ml in HCC patients, and AFP was 0.3 （0.1,1.0）ng/ml, CD147 was （2.98±0.80）ng/ml, VEGF was 10（0,10）pg/ml in healthy control. Three bio- markers in HCC were significantly higher than healthy controls. Conclusion A high sensitive luminex liquichip analysis system for three kinds of tumor markers combined detection is established.
同期刊论文项目
同项目期刊论文
期刊信息
位置：